Introduction
============

The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III \[ATP-III\]) provides evidence-based recommendations on the management of high blood cholesterol and related disorders. ATP-III reports have identified low-density lipoprotein cholesterol (LDL-C) as the primary target of cholesterol-lowering therapy. Many prospective studies have shown that a high serum LDL-C concentration is a major risk factor for coronary heart disease (CHD).[@b1-vhrm-10-089],[@b2-vhrm-10-089] On the basis of accumulated evidence from epidemiological studies and randomized control trials, the ATP-III has proposed a treatment algorithm for LDL-C-lowering therapy. According to the ATP-III algorithm, persons are categorized into three risk categories: 1) established CHD and CHD risk equivalents; 2) multiple (two or more) risk factors; and 3) zero to one risk factor. CHD risk equivalents include noncoronary forms of clinical atherosclerotic disease, diabetes, and multiple (two or more) CHD risk factors with 10-year risk for CHD \>20%. All persons with CHD or CHD risk equivalents may be considered to be at high risk.[@b3-vhrm-10-089]

The NCEP ATP-III guidelines for CHD risk stratification incorporate the concept of global risk assessment to determine the intensity and appropriateness of lipid-modifying treatment. According to the NCEP ATP-III, the LDL-C optimal goal for patients is \<100 mg/dL, with ranges near optimal or above optimal of 100--129 mg/dL, borderline high of 130--159 mg/dL, high of 160--189 mg/dL, and very high of ≥190 mg/dL. The risk for cardiovascular disease (CVD) increases further when elevated LDL-C is coupled with other risk factors, such as being overweight, low high-density lipoprotein cholesterol (HDL-C) levels, high triglyceride (TG) levels, lack of exercise, high-sensitivity C-reactive protein (hs-CRP), high fibrinogen, hypertension, etc.[@b4-vhrm-10-089]

According to the American Heart Association, an estimated one in three Americans have one or more types of CVD, and approximately half of them are estimated to be age 60 or older.[@b5-vhrm-10-089] Based on data from the ATP-III, only about a third of treated patients achieve their LDL-C goal, and less than 20% of those patients maintain their LDL-C goal. Statins are hypolipidemic agents and are used for treating hyperlipidemia and preventing cardiovascular events.[@b6-vhrm-10-089]--[@b8-vhrm-10-089] The use of statin therapy is increasing,[@b9-vhrm-10-089] and its side effects are becoming more evident to clinicians. Intensive-dose statin therapy has been shown to reduce cardiovascular events;[@b10-vhrm-10-089] however, prolonged use of statins at high dose may induce muscle and liver damage[@b11-vhrm-10-089],[@b12-vhrm-10-089] and has been associated with an increased risk of developing diabetes mellitus.[@b10-vhrm-10-089],[@b13-vhrm-10-089]--[@b16-vhrm-10-089] A clinical trial of diabetic patients receiving intensive statin therapy reported a loss of glycemic control.[@b17-vhrm-10-089] A recent study reported that patients with hypercholesterolemia receiving a high dose of atorvastatin developed insulin resistance as well as higher insulin and hemoglobin A~1c~ levels compared with patients receiving low dosage or placebo.[@b18-vhrm-10-089] Thus, further investigation for new and alternative hypolipidemic agents, with better tolerability and fewer side effects, is warranted.

Pantethine is a naturally occurring physiological compound synthesized in the body from pantothenic acid (vitamin B5). It is thought that pantethine, in conjunction with the intermediary cysteamine, inhibits acetyl-coenzyme (CoA) carboxylase and 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, thereby affecting TG synthesis and lipoprotein metabolism.[@b19-vhrm-10-089]--[@b21-vhrm-10-089] Pantethine increases CoA levels within the cells,[@b22-vhrm-10-089] which favorably modifies lipoprotein metabolism.[@b23-vhrm-10-089],[@b24-vhrm-10-089] However, the full mechanism of action of pantethine in lowering cholesterol levels is not fully understood. Since homocysteine is believed to contribute to the onset and progression of atherosclerosis[@b25-vhrm-10-089] and is involved in the biosynthesis of CoA,[@b26-vhrm-10-089] it is possible that pantethine impacts homocysteine.

Several studies report that pantethine is a well-tolerated hypolipidemic agent that may decrease serum total cholesterol (TC), TG, LDL-C, apolipoprotein (Apo) A-I, and Apo-B.[@b27-vhrm-10-089]--[@b32-vhrm-10-089] A clinical study of diabetic hyperlipidemic patients on dialysis, treated with 900 mg/day of pantethine reported decreases in TC, very-low density lipoprotein cholesterol (VLDL-C), and TG.[@b33-vhrm-10-089] Pantethine may be a safe and effective alternative treatment of hyperlipidemia in patients with health issues who are not eligible for statin therapy.

Pantethine is known to be safe and effective[@b33-vhrm-10-089] and has been used as a medicine in Japan for over 40 years. In the US, oral pantethine (Pantesin®; Daiichi Fine Chemical Co, Ltd, Toyama, Japan) has been available as a nutritional supplement since 1992. In a recent randomized clinical study in a North American population of participants at conventional low to moderate CVD risk, pantethine produced significant and sustained reductions in LDL-C, TC, and Apo-B.[@b34-vhrm-10-089] Based on previous studies on the efficacy of pantethine in participants with CVD risk and its record of tolerability, we hypothesized that oral pantethine would improve cholesterol metabolism in North American subjects at low to moderate CVD risk who are eligible for statin therapy according to the NCEP guidelines. More specifically, we hoped to clarify the benefits of the combination of oral pantethine with a Therapeutic Lifestyle Change (TLC) diet for individuals who are candidates for statins, in order to establish a treatment option with less serious adverse events (AEs).[@b4-vhrm-10-089]

Material and methods
====================

Study objectives
----------------

The primary end point in this study was the change in fasting LDL-C levels from baseline over a 16-week supplementation period. Secondary end points included lipoprotein parameters (fasting: TC, HDL-C, TG, VLDL-C, lipoprotein(a), and Apo-B), anthropomorphic measures (weight; waist circumference; and skin folds, using the Yuhasz skin-fold test),[@b35-vhrm-10-089] vital signs (heart rate and blood pressure), and laboratory tests for efficacy and safety (complete blood count \[CBC\] including platelets, hs-CRP, aspartate aminotransferase \[AST\], alanine transaminase \[ALT\], homocysteine, creatine kinase \[CK\], and coenzyme Q~10~ \[CoQ~10~\]).

Study design
------------

This study was conducted in compliance with the International Conference on Harmonisation Guidance for Good Clinical Practice and according to the guidelines laid down in the Declaration of Helsinki and its amendments. This study was reviewed by Health Canada's Natural Health Products Directorate (Ottawa, ON, Canada), and the Notice of Authorization was received on December 18, 2008. The Institutional Review Board Services (Aurora, ON, Canada) ethics committee approved all procedures in this study involving human subjects on December 22, 2008. All participants provided written informed consent prior to any study activities. This study was a randomized, triple-blinded, placebo-controlled trial with a 4-week diet lead-in followed by a 16-week treatment period. The study was conducted at two sites, KGK Synergize (London, ON, Canada) and SIBR Research (Bradenton, FL, USA).

Participants
------------

Male and female participants enrolled in the study were recruited at the two research locations. The subjects were screened by physical examination and blood analysis to determine their eligibility, and 32 participants were randomized into the study. The physical examination included height, weight, waist circumference, skin-fold measurement, heart rate, and blood pressure. Fasting blood work included CBC, TC, HDL-C, LDL-C, TG, AST, ALT, glucose, creatinine, CK, and CoQ~10~. Females were required to have a negative result for the serum human chorionic gonadotropin test for pregnancy.

Subjects were eligible for enrollment if they were ≥21 years of age and had LDL-C levels above the goal for TLC diet changes: low Framingham Risk Score (FRS) (\<10% per decade) or zero to one nonlipid risk factors, and LDL-C \>160 mg/dL; or moderate FRS (\>10 but \<20% per decade) or two or fewer nonlipid risk factors, and an LDL-C \>130 mg/dL. Subjects were excluded if they had a history of gastrointestinal surgery, type I or type II diabetes, blood disorders, concurrent renal and/or liver failure, or significantly abnormal liver function tests; were using statins or other prescription medications to treat hyperlipidemia; had a diet high in soy or other food, supplements or natural products known to reduce cholesterol, or had followed the TLC diet within 12 weeks before the start of the study; were immune-compromised; used oral or injectable systemic corticosteroids, unless on a stable dose for more than 12 weeks; had CVD; had uncontrolled or untreated hypertension, defined as systolic pressure \>160 mmHg or diastolic pressure \>100 mmHg; had used prescribed medication or over-the-counter supplements for weight loss within the 12 weeks prior to randomization; had allergy or sensitivity to the investigational product ingredients; or had any other condition that, in the investigator's opinion, adversely affected the subjects' ability to complete the study or its measures, or that posed a significant risk to the subject.

Dietary intervention and diet lead-in
-------------------------------------

A registered dietician instructed participants on the TLC diet. The optional addition of 10 to 25 g/day viscous fibers and/or 2 g/day plant stanols/sterols and/or soy protein was excluded from the prescribed diet. Participants were required to follow the TLC diet for 4 weeks leading into the study (screening to baseline) so that the effect of the TLC diet on their lipid levels could be evaluated prior to the start of the supplementation. This eliminated potential contributions from varied diets between participants. The participants were required to remain on the TLC diet for the duration of the study and were required to complete a 3-day food record for any 2 weekdays and 1 weekend day before the next visit. To promote compliance with the TLC diet, the food records were completed and returned for review and counsel by the dietician at each study visit. The food records were analyzed for average daily energy intake of protein, fats, carbohydrates, and fiber.

Randomization and blinding
--------------------------

On completion of the 4-week TLC diet lead-in, participants were randomized in a 1:1 ratio to receive either pantethine or the placebo. A blocking factor of two was used for randomization. To preserve blinding, the investigational tablets and nonactive placebo tablets were identical in appearance and sealed in identical blister packs identifiable only by randomization number.

Investigational product
-----------------------

The investigational product was the pharmaceutical grade, proprietary product Pantesin HF55. Each tablet contained 300 mg of active ingredient and was manufactured by Eagle Nutritionals (Carlstadt, NJ, USA). The blister packs were manufactured by Generic Pharmaceutical Services (Hauppauge, NY, USA) and were labeled in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines as well as applicable local regulations. Each blister pack contained two active ingredient tablets and one placebo tablet (600 mg/day dose, from weeks 1 to 8), three active ingredient tablets (900 mg/day dose from weeks 9 to16), or three placebo tablets. The participants in both groups took one tablet three times per day for the entire study period, from baseline to week 16. Compliance was assessed by reviewing the returned blister packs.

Clinical assessments
--------------------

Participants returned to the clinic at weeks 0, 2, 4, 8, 12, and 16 and upon each visit, fasting (12 hours) blood was collected for analysis (Gamma-Dynacare Medical Laboratories, London, ON, Canada) of the lipid panel (TC, HDL-C, LDL-C, TG, VLDL-C, Apo-B, and lipoprotein), and markers of safety; CBC, electrolytes, and liver and kidney function tests. TG was analyzed by an enzymatic colorimetric assay performed on a Roche P800 Clinical Chemistry Analyzer, VLDL-C was calculated from TG values (by dividing TG by 2.18) and lipoprotein was measured by a nephelometric assay performed on a Siemens BN II Nephelometer. hs-CRP, homocysteine, and CoQ10 were measured at weeks 0, 4, 8, 12, and 16. hsCRP was analyzed using a Dade Behring BNII nephelometer and homocysteine analyzed using FPIA technology (Gamma-Dynacare Medical Laboratories). Total CoQ10 analysis was performed by HPLC with UV detection by KGK Synergize Laboratory (London, ON, Canada). The HPLC method was adapted from Mosca et al.[@b36-vhrm-10-089]

Adverse events (AE) were recorded, by the participants, in diaries and were monitored by the investigator from the time they had at least one dose of study product until the end of the treatment period. Unfavorable signs and symptoms, including any abnormal laboratory findings, disease, or the worsening of any preexisting conditions that were temporally associated with the use of the investigational product, were considered AEs. The study investigator assessed AEs and designated the causality relationship with the investigational product as most probable, probable, possible, unlikely, or unrelated.

Statistical analyses
--------------------

Between-group analyses of demographic and baseline characteristics were performed using a covariate adjustment for a comparison of study end points, and where baseline values were missing, the values obtained from the screening visit were used.

Between-group analyses of primary and secondary end points and safety parameters were adjusted for baseline, and groups compared using an unpaired *t*-test. The Anderson--Darling test was used to determine whether data were non-normally distributed. Where data was non-normally distributed, between-group comparisons were made using a nonparametric test. Within-group comparisons were made using Student's *t*-test or Wilcoxon signed-ranks test, as appropriate. The "last value carried forward" technique was also applied where data was missing subsequent to week 2, using the last available postrandomization observation for statistical analyses.

A between-group analysis of the proportion of participants experiencing adverse events was performed using the Fisher's exact test. All statistical analyses were performed using *R*, and probability values \<0.05 were considered statistically significant.

Results
=======

The participants enrolled in this study were predominantly white females; however, there was no statistically significant difference between groups at baseline ([Table 1](#t1-vhrm-10-089){ref-type="table"}). A total of 32 participants completed the 4-week TLC diet lead-in and were randomized in a 1:1 ratio to receive either pantethine or placebo. Finally, 24 participants completed the 16-week supplementation ([Figure 1](#f1-vhrm-10-089){ref-type="fig"}).

Lipid profile
-------------

There was a reduction in plasma LDL-C, TC, and non-HDL-C levels in all participants during the 4-week TLC diet lead-in from screening to baseline ([Figure 2](#f2-vhrm-10-089){ref-type="fig"}). The participants on pantethine demonstrated a significant decrease in TC at week 16 (*P*=0.040) and LDL-C at weeks 8 and 16 (*P*=0.020 and *P*=0.006, respectively) compared with placebo. Non-HDL-C showed decreasing trends at week 8 (*P*=0.102) and week 12 (*P*=0.145), with values reaching significance by week 16 (*P*=0.042), in the pantethine group compared with placebo. Homocysteine levels for both groups did not change significantly from baseline to week 16.

Within groups, all participants demonstrated an insignificant decrease in their lipid profile from screening to baseline, during the 4-week lead-in TLC diet period. At week 4, a 6% decrease in TC (*P*=0.005), 11% decrease in LDL-C (*P*=0.002), 7% decrease in non-HDL-C (*P*=0.005), and 4% decrease in Apo-B (*P*=0.041) from baseline was seen in the pantethine group. These decreases continued to week 8, week 12, and week 16 for TC (6% \[*P*=0.007\], 7% \[*P*=0.031\], and 6% \[*P*=0.041\], respectively), LDL-C (11% \[*P*\<0.001\], 11% \[*P*=0.012\], and 11% \[*P*=0.004\], respectively), and non-HDL-C (8% \[*P*=0.002\], 9% \[*P*=0.022\], and 8% \[*P*=0.035\], respectively). Improvements in LDL-C reached between-group significance at weeks 8 (*P*=0.027) and 16 (*P*=0.010). The within-group decrease in Apo-B showed a trend towards significance at week 8 (5% \[*P*=0.106\]) and decreased by 8% at week 12, reaching significance (*P*=0.032). The within-group decrease in the ratio of TC to HDL-C and non-HDL-C to HDL-C reached significance at week 8 (8% \[*P*=0.004\] and 9% \[*P*=0.010\], respectively) and week 12 (7% \[*P*=0.028\] and 9% \[*P*=0.030\], respectively). The participants on placebo showed a 2% decrease in LDL-C concentrations at week 8 and a 3% increase by week 16; however, these changes did not reach significance. There were no significant within-group changes, during the study period, in HDL-C, TG, VLDL-C, or lipoprotein(a) levels in the participants on pantethine.

A subgroup analysis based on sex revealed that females supplemented with pantethine had significantly lower percent TC at weeks 4 (7% \[*P*=0.003\]), 8 (8% \[*P*=0.001\]), 12 (9% \[*P*=0.012\]), and 16 (8% \[*P*=0.010\]) compared with baseline. The within-group difference at week 16 translated into an 8% decrease in TC compared with those on placebo (*P*=0.021). Females showed a significant decrease in LDL-C at weeks 4 (*P*\<0.001), 8 (*P*\<0.001), 12 (*P*\<0.006), and 16 (*P*\<0.001) compared with baseline. These changes resulted in a significant 12% decrease of LDL-C at week 8 (*P*=0.016) and a 13% decrease at week 16 (*P*=0.003) compared with placebo. Significant within-group changes in non-HDL-C were also seen in females at weeks 4, 8, 12, and 16. These changes were significantly better than placebo at week 16 (*P*=0.018), showing an 11% decrease in non-HDL-C in the females on pantethine. The males on pantethine showed greater within-group decreases in LDL-C at weeks 2 and 4, but these changes did not reach significance between groups.

Anthropomorphic parameters and blood chemistry
----------------------------------------------

There were no between- or within-group statistical differences in blood pressure, heart rate, waist circumference, or body mass index (BMI) during the study. The biochemistry and clinical chemistry of the participants showed there were no clinically relevant differences between the participants in the two groups ([Table 2](#t2-vhrm-10-089){ref-type="table"}). CoQ10 increased from baseline to weeks 4, 8, 12, and 16 in participants on pantethine (*P*=0.028, *P*=0.001, *P*=0.008, and *P*=0.001, respectively) and placebo (*P*=0.019, *P*=0.012, *P*=0.042, and *P*=0.027, respectively); however, these increases were not statistically significant between groups ([Table 2](#t2-vhrm-10-089){ref-type="table"}).

Adverse events
--------------

In the current study, a total of one symptom potentially attributed to study medication was recorded in one participant in the placebo group. A total of two symptoms (diarrhea and flatulence) potentially attributed to the study medication were reported by participants on pantethine. The diarrhea was moderate in intensity, experienced for 3 days during the 600 mg/day dosage period, and did not recur when the dosage was escalated. The flatulence reported by one participant was experienced during both dosage periods, was mild in intensity, and resolved prior to the end of the study. A single mild episode of neutropenia was found in a participant on placebo.

Discussion
==========

It is well established that elevated levels of plasma lipids play a major role in the development and progression of atherosclerotic disease.[@b37-vhrm-10-089]--[@b39-vhrm-10-089] Lowering LDL-C levels in an individual reduces the CVD risk and incidence of cardiovascular outcomes.[@b4-vhrm-10-089],[@b40-vhrm-10-089],[@b41-vhrm-10-089] Currently, cholesterol-lowering drugs, such as statins, lower LDL-C and the prevalence of cardiovascular events.[@b6-vhrm-10-089]--[@b8-vhrm-10-089] However, intensive statin use has been associated with onset of diabetes, muscle and liver damage, and cognitive impairment.[@b10-vhrm-10-089]--[@b12-vhrm-10-089],[@b42-vhrm-10-089]

The ATP III recommends that the first line of treatment for a patient with abnormal LDL-C should be the TLC diet. Thereafter, individuals are categorized by risk factor profile and/or FRS and are considered to be eligible for statin therapy if LDL-C levels are above a specific goal.[@b34-vhrm-10-089] A previous study on pantethine investigated the efficacy of pantethine treatment in low-risk (FRS 10-year risk \<10% and LDL \<160 mg/dL) or moderate-risk (FRS 10-year risk \>10% but \<20% and LDL \<130 mg/dL) subjects eligible for TLC diet initiation but not for statin therapy. In these participants, pantethine supplementation for 16 weeks significantly lowered TC and LDL-C over and above the TLC diet alone.[@b34-vhrm-10-089] The current study investigated the efficacy of pantethine on subjects eligible for statin therapy and therefore, with LDL-C levels above the ATP III goal for TLC diet changes (low FRS \[\<10% per decade\] or zero to one nonlipid risk factor, and LDL-C \>160 mg/dL; or moderate FRS \[\>10 but \<20% per decade\] or two or fewer nonlipid risk factors, and LDL-C \>130 mg/dL). The results of our study confirmed the hypothesis that pantethine would significantly improve cholesterol metabolism, by lowering TC and LDL-C, without causing serious AEs in low- and moderate-CVD risk individuals eligible for statin therapy. Pantethine did not have an effect on TG levels, possibly because the enrolled participants had normal TG levels at baseline. The primary conclusion of this investigation is that the TLC diet alone did not produce a significant change in the lipid profile, but pantethine coupled with the TLC diet significantly decreased TC and LDL-C in participants during the 16-week study.

The Framingham Offspring Study has suggested a sex effect on LDL-C.[@b43-vhrm-10-089] The pantethine group had a higher female to male ratio than did the placebo group. A subgroup analysis on sex showed that there was no significant difference in LDL-C at screening or after the 4-week TLC diet lead-in, with participants in both groups having similar LDL-C values at baseline. However after the initiation of the supplementation, the pantethine group showed greater within-group decreases in LDL-C, reaching 11% by week 4. The female participants showed a 13% decrease by week 8, which was then maintained at weeks 12 and 16. These within-group percentage changes were significant between groups at week 8 and week 16, suggesting that the improvements in LDL-C in females were associated with pantethine supplementation. The Apo-B levels in the females on pantethine also showed significant decreases from baseline at weeks 2, 4, 8, 12, and 16; those on placebo showed an increase in Apo-B during the study. The male participants on pantethine did not show differences in lipid parameters, possibly due to the smaller sample numbers.

The increase from 600 mg/day in weeks 1 through 8 to 900 mg/day in weeks 9 through 16 did not appear to provide any additional or measurable benefit with respect to improvement in lipid parameters at week 12; however, significant improvements were observed by week 16. These results suggest that the optimal benefit in low to moderate risk participants eligible for statin therapy is achieved at a 300 mg twice per day dose schedule; however, levels of pantethine in the blood were not measured during the treatment period. According to the NCEP ATP-III, the initial LDL-C levels of the randomized participants in this trial were in the high category. At 16 weeks after randomization, the participants receiving placebo remained in the high category, while the participants receiving pantethine decreased to the borderline high category. The participants receiving pantethine demonstrated a reduction of LDL-C levels that reached 11% below baseline at week 16, a significant result compared with that of the participants on placebo, who showed a 3% increase. The length of this trial was a shortcoming of the study as after the 16 weeks of pantethine administration, the measured parameters had not plateaued, making prediction of the long-term outcome of pantethine on lipidemia difficult. Future clinical trials investigating the long-term administration of pantethine may demonstrate an even more robust decline in LDL-C and TC levels. A small sample size and absence of sex stratification were also limitations of this study design. Prior clinical studies have reported that for every 1% reduction of LDL-C levels, an approximate 1% relative risk reduction of major CHD events is attained.[@b44-vhrm-10-089]--[@b52-vhrm-10-089] Participants receiving pantethine also had a 6% decrease in TC and 8% decrease in non-HDL-C, which was significantly different from participants on placebo who only had 2% and 1% decreases, respectively. Further evidence in the literature has demonstrated conclusively that lowering serum cholesterol concentration results in substantial protection from ischemic heart disease.[@b3-vhrm-10-089],[@b40-vhrm-10-089],[@b53-vhrm-10-089]

There were no significant changes in homocysteine levels from baseline to week 16 and levels remained within the normal range (≤15 μmol/L) for both groups during this study. The effect of homocysteine on CVD risk remains uncertain. Homocysteine level is a prognostic marker of mortality and CVD events in patients with preexisting CVD risk factors.[@b54-vhrm-10-089] On the other hand, meta-studies have shown that reducing homocysteine levels by vitamin supplementation did not reduce the risk of major cardiovascular events or overall mortality in patients with vascular disease.[@b55-vhrm-10-089],[@b56-vhrm-10-089] As the mechanisms of action of pantethine in lowering cholesterol levels are not fully understood, it was important to consider the impact of pantethine supplementation, if any, on homocysteine.

The adverse events attributed to the study product were 6.3% for placebo and 12.5% for pantethine. In the placebo group, an unresolved mild blood and bone marrow AE (neutropenia) was observed. In the pantethine group, flatulence and diarrhea were reported, but these two events resolved during the study. The AEs reported in this study were consistent with the previously reported AEs of pantethine.[@b32-vhrm-10-089],[@b34-vhrm-10-089] Previous clinical studies have demonstrated that pantethine is well tolerated, with a low occurrence of side effects at dosages from 600 to 1,200 mg/day.[@b32-vhrm-10-089],[@b34-vhrm-10-089]

Some of the health risks of prolonged use of statins at high dosages include myalgias and increased risk of developing diabetes mellitus. These are related to concomitant lowering of in vivo CoQ~10~ production. Though not significant between groups, CoQ~10~ levels significantly increased from baseline to week 4 and remained increased at week 16 in both the pantethine and placebo group. It is possible that the TLC diet may have provided foods containing higher levels of CoQ~10~ compared with the meals the participants were consuming prior to the start of the study. Furthermore, plasma CoQ~10~ levels are not necessarily a reflection of tissue CoQ~10~ levels.[@b57-vhrm-10-089] Unlike statins, which are HMG-CoA reductase inhibitors that block the biosynthesis of CoQ~10~, pantethine did not block CoQ~10~.[@b58-vhrm-10-089] Since pantethine does not affect CoQ~10~ production, the combined use of pantethine and a low dose of statins may act synergistically to lower LDL-C while minimizing the adverse effects related to a high dose of statins. Further research is required to test this hypothesis.

The mechanism of action of pantethine in its role as a lipid-lowering agent is yet to be clarified. It has been postulated that pantethine acts by inhibiting the enzymes acetyl-CoA carboxylase and HMG-CoA reductase, thus modifying lipoprotein metabolism.[@b22-vhrm-10-089],[@b34-vhrm-10-089] Others have reported that neuropeptides activated by pantethine have an effect on calcitonin gene-related peptide (CGRP) and vasoactive intestinal polypeptide (VIP).[@b53-vhrm-10-089] Further research is required to determine whether the enhancement of blood flow and gut motility by both CGRP and VIP may be associated with improvements in the CVD end points measured in this study.[@b54-vhrm-10-089],[@b55-vhrm-10-089] Recently, gut microbiota and microbial metabolome have been identified to play important roles in CVD, diabetes, and cancer.[@b59-vhrm-10-089],[@b60-vhrm-10-089] Evidence from repeated randomized clinical studies have shown that probiotic bacterial strains, such *Lactobacillus* and *Bifidobacterium*, aid in decreasing lipids in hyperlipidemic adults.[@b61-vhrm-10-089],[@b62-vhrm-10-089] Pantethine has been reported to promote the survival and growth of various beneficial gut microorganisms.[@b62-vhrm-10-089]--[@b65-vhrm-10-089] In vitro studies have identified a role for pantethine as a growth factor for *Lactobacillus bulgaricus* and *Bifidobacterium bifidum*, in promoting their survival and growth.[@b64-vhrm-10-089],[@b65-vhrm-10-089] These results, together with results of the human studies on pantethine, suggest the possible linkage of multiple mechanisms of actions in the various health benefits of pantethine.

Conclusion
==========

This study confirms that pantethine lowers CVD risk markers in low to moderate CVD risk participants who are candidates for statins according to the NCEP guidelines. Compared with placebo, pantethine-treated participants demonstrated significant declines in LDL-C, HDL-C, and TC levels after 16 weeks of treatment. Moreover, unlike statins, which deplete CoQ~10~ to detrimental levels, both the pantethine and placebo groups significantly increased their CoQ~10~ levels above baseline. This study demonstrated that the TLC diet alone did not significantly affect lipid profiles but in conjunction with pantethine supplementation, significantly decreased lipid levels. Supplementation with pantethine may therefore be considered as an optional adjunctive therapy for patients with low to moderate CVD risk.
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![Subject disposition.\
**Notes:** \*Two subjects withdrew from the study due to adverse events, and one moved out of the city. The adverse events that were reported were: cold symptoms (n=1); and presence of blood in the stool (n=1). \*\*Four subjects withdrew from the study due to adverse events. The adverse events that were reported were: LDL-C increased to ATP III high-risk category (n=3); and one subject did not wish to continue study after being ill with strep throat (n=1). \*\*\*One subject withdrew from the study due to an increase in LDL-C to ATP III high-risk category. The black boxes represent the pantethine tablets which was the investigational product and the white boxes represent the placebo. In order to maintain blinding all subjects received 3 tablets. At week 8 the dose was increased in the pantethine group so they received three pantethine tablets (three black boxes).\
**Abbreviations:** ATP III, Adult Treatment Panel III (Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in adults); LDL-C, low-density lipoprotein cholesterol; TLC, Therapeutic Lifestyle Change.](vhrm-10-089Fig1){#f1-vhrm-10-089}

![Changes in the serum (**A**) TC, (**B**) LDL-C, (**C**) non-HDL-C, and (**D**) Apo-B levels at screening, baseline, and weeks 2, 4, 8, 12 and 16 of the study period.\
**Notes:** Data are represented as the mean ± SEM. Triangle (▲) represents placebo, and square (■) represents pantethine. Asterisk (\*) indicates a statistically significant (*P*\<0.05) between-group statistical comparison, using baseline as a covariate.\
**Abbreviations:** Apo-B, apolipoprotein B; LDL-C, low-density lipoprotein cholesterol; non-HDL-C, non-high-density lipoprotein cholesterol; SEM, standard error of the mean; TC, total cholesterol.](vhrm-10-089Fig2){#f2-vhrm-10-089}

###### 

Baseline physical characteristics of participants in the pantethine and placebo groups

  Characteristic   Pantethine (n=16) mean ± SD   Placebo (n=16) mean ± SD   *P*-value[a](#tfn1-vhrm-10-089){ref-type="table-fn"}
  ---------------- ----------------------------- -------------------------- ------------------------------------------------------
  Age (years)      54.4±7.3                      47.2±12.1                  0.051
  Height (cm)      164.8±6.9                     169.3±7.5                  0.083
  Sex (%)                                                                   
   Female          87.50                         56.25                      0.113
   Male            12.50                         43.75                      
  Race (%)                                                                  
   White           87.50                         93.75                      \>0.999
   Other           12.50                         6.25                       \>0.999

**Notes:**

Between-group (adjusted to baseline) statistical comparisons were conducted using unpaired *t*-test. Probability values *P*\<0.05 are significant.

**Abbreviation:** SD, standard deviation.

###### 

Biochemistry and clinical characteristics of participants in the pantethine and placebo groups

                                Pantethine            Placebo               *P*-value
  ----------------------------- --------------------- --------------------- ---------------------------------------------------
  Hemoglobin (g/L)                                                          
   Screening                    \(16\) 139.90±5.90    \(16\) 144.60±13.30   --
   Baseline                     \(16\) 138.40±6.10    \(16\) 140.90±11.30   0.508
   Week 2                       \(16\) 138.40±7.20    \(16\) 141.90±12.20   0.339
   Week 4                       \(16\) 137.10±8.30    \(16\) 141.60±10.70   0.201
   Week 8 dose escalation       \(16\) 136.50±9.50    \(13\) 141.20±12.70   0.260
   Week 12                      \(15\) 135.50±9.30    \(9\) 141.00±13.60    0.253
   Week 16 end of study         \(15\) 134.60±8.20    \(9\) 142.20±13.00    0.090
  Hematocrit (L/L)                                                          
   Screening                    \(16\) 0.408±0.020    \(16\) 0.422±0.039    --
   Baseline                     \(16\) 0.406±0.023    \(16\) 0.415±0.036    0.412
   Week 2                       \(16\) 0.406±0.027    \(16\) 0.414±0.032    0.444
   Week 4                       \(16\) 0.403±0.028    \(16\) 0.414±0.031    0.289
   Week 8 dose escalation       \(16\) 0.402±0.032    \(13\) 0.414±0.036    0.357
   Week 12                      \(15\) 0.400±0.041    \(9\) 0.414±0.044     0.428
   Week 16 end of study         \(15\) 0.402±0.039    \(9\) 0.424±0.039     0.184
  White blood cells (10^9^/L)                                               
   Screening                    \(16\) 6.19±1.52      \(16\) 7.14±2.31      --
   Baseline                     \(16\) 5.86±1.10      \(16\) 6.46±1.85      0.273
   Week 2                       \(16\) 5.96±1.33      \(16\) 6.29±2.30      0.821
   Week 4                       \(16\) 6.02±0.89      \(16\) 6.51±2.27      0.533
   Week 8 dose escalation       \(16\) 5.83±1.19      \(13\) 6.54±1.84      0.218
   Week 12                      \(15\) 5.68±1.48      \(9\) 5.87±2.37       0.530
   Week 16 end of study         \(15\) 5.89±1.58      \(9\) 6.10±2.08       0.835
  Red blood cells (10^12^/L)                                                
   Screening                    \(16\) 4.52±0.28      \(16\) 4.70±0.47      --
   Baseline                     \(16\) 4.45±0.23      \(16\) 4.61±0.38      0.173
   Week 2                       \(16\) 4.46±0.31      \(16\) 4.59±0.36      0.293
   Week 4                       \(16\) 4.40±0.28      \(16\) 4.59±0.35      0.115
   Week 8 dose escalation       \(16\) 4.40±0.32      \(13\) 4.57±0.36      0.189
   Week 12                      \(15\) 4.37±0.37      \(9\) 4.63±0.32       0.087
   Week 16 end of study         \(15\) 4.35±0.30      \(9\) 4.71±0.30       0.011[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
  MCV (fL)                                                                  
   Screening                    \(16\) 90.50±2.70     \(16\) 90.10±3.70     --
   Baseline                     \(16\) 91.30±3.00     \(16\) 89.90±3.40     0.242
   Week 2                       \(16\) 91.20±3.10     \(16\) 90.10±3.80     0.401
   Week 4                       \(16\) 91.20±3.20     \(16\) 90.40±3.90     0.525
   Week 8 dose escalation       \(16\) 91.50±3.30     \(13\) 90.80±4.60     0.626
   Week 12                      \(15\) 91.90±3.80     \(9\) 89.30±4.80      0.162
   Week 16 end of study         \(15\) 92.00±4.50     \(9\) 90.00±5.30      0.332
  MCH (pg)                                                                  
   Screening                    \(16\) 31.02±1.18     \(16\) 30.76±1.67     --
   Baseline                     \(16\) 31.14±1.16     \(16\) 30.66±1.40     0.292
   Week 2                       \(16\) 31.07±1.15     \(16\) 30.96±1.49     0.813
   Week 4                       \(16\) 31.18±1.15     \(16\) 30.97±1.74     0.687
   Week 8 dose escalation       \(16\) 31.07±1.25     \(13\) 30.95±1.81     0.831
   Week 12                      \(15\) 31.10±1.18     \(9\) 30.37±1.53      0.199
   Week 16 end of study         \(15\) 31.02±1.13     \(9\) 30.10±1.49      0.100
  MCH concentration (g/L)                                                   
   Screening                    \(16\) 342.50±5.80    \(16\) 341.70±6.10    --
   Baseline                     \(16\) 341.30±8.60    \(16\) 340.60±6.90    0.570
   Week 2                       \(16\) 340.90±8.90    \(16\) 343.40±7.60    0.387
   Week 4                       \(16\) 341.80±6.60    \(16\) 342.00±8.10    0.943
   Week 8 dose escalation       \(16\) 339.60±7.90    \(13\) 341.00±8.90    0.648
   Week 12                      \(15\) 339.10±15.20   \(9\) 341.00±14.30    0.698
   Week 16 end of study         \(15\) 337.10±14.80   \(9\) 334.90±13.50    0.611
  RDW (%)                                                                   
   Screening                    \(16\) 13.55±0.75     \(16\) 13.59±0.97     --
   Baseline                     \(16\) 13.76±0.94     \(16\) 13.73±1.03     0.663
   Week 2                       \(16\) 13.82±0.85     \(16\) 13.81±1.06     0.971
   Week 4                       \(16\) 13.84±0.92     \(16\) 13.86±1.11     0.945
   Week 8 dose escalation       \(16\) 13.98±1.05     \(13\) 13.64±1.20     0.262
   Week 12                      \(15\) 13.97±1.23     \(9\) 13.96±1.23      \>0.999
   Week 16 end of study         \(15\) 14.09±1.16     \(9\) 14.08±1.36      0.952
  Platelet count (10^9^/L)                                                  
   Screening                    \(16\) 302.00±66.00   \(16\) 276.00±79.00   --
   Baseline                     \(15\) 285.00±59.00   \(16\) 260.00±67.00   0.287
   Week 2                       \(16\) 293.00±61.00   \(16\) 262.00±78.00   0.222
   Week 4                       \(16\) 284.00±68.00   \(16\) 263.00±70.00   0.346
   Week 8 dose escalation       \(16\) 282.00±68.00   \(13\) 273.00±81.00   0.735
   Week 12                      \(15\) 272.00±62.00   \(9\) 247.00±79.00    0.221
   Week 16 end of study         \(15\) 267.00±67.00   \(9\) 269.00±96.00    0.907
  MPV (fL)                                                                  
   Screening                    \(16\) 8.37±0.81      \(16\) 8.99±0.88      --
   Baseline                     \(15\) 8.57±1.10      \(16\) 9.04±0.91      0.208
   Week 2                       \(16\) 8.49±0.83      \(16\) 9.14±0.77      0.028[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
   Week 4                       \(16\) 8.52±0.86      \(16\) 9.22±0.91      0.032[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
   Week 8 dose escalation       \(16\) 8.54±0.76      \(13\) 9.05±0.65      0.063
   Week 12                      \(15\) 8.63±0.93      \(9\) 8.97±0.43       0.436
   Week 16 end of study         \(15\) 8.66±0.94      \(9\) 9.04±0.55       0.353
  Neutrophils (10^9^/L)                                                     
   Screening                    \(16\) 3.57±1.07      \(16\) 4.62±1.93      --
   Baseline                     \(16\) 3.47±0.91      \(16\) 3.94±1.36      0.257
   Week 2                       \(16\) 3.46±0.99      \(16\) 3.96±1.87      0.706
   Week 4                       \(16\) 3.65±0.71      \(16\) 4.14±1.75      0.307
   Week 8 dose escalation       \(16\) 3.41±1.00      \(13\) 4.17±1.46      0.106
   Week 12                      \(15\) 3.30±1.36      \(9\) 3.58±1.43       0.676
   Week 16 end of study         \(14\) 3.33±1.03      \(9\) 3.60±1.24       0.567
  Lymphocytes (10^9^/L)                                                     
   Screening                    \(16\) 1.99±0.51      \(16\) 1.90±0.51      --
   Baseline                     \(16\) 1.87±0.44      \(16\) 1.94±0.53      0.714
   Week 2                       \(16\) 1.90±0.53      \(16\) 1.73±0.47      0.345
   Week 4                       \(16\) 1.79±0.40      \(16\) 1.82±0.51      0.878
   Week 8 dose escalation       \(16\) 1.86±0.39      \(13\) 1.82±0.51      0.817
   Week 12                      \(15\) 1.79±0.63      \(9\) 1.74±0.85       0.474
   Week 16 end of study         \(14\) 2.07±1.04      \(9\) 1.90±0.94       0.378
  Monocytes (10^9^/L)                                                       
   Screening                    \(16\) 0.40±0.14      \(16\) 0.42±0.14      --
   Baseline                     \(16\) 0.34±0.13      \(16\) 0.39±0.12      0.350
   Week 2                       \(16\) 0.37±0.13      \(16\) 0.39±0.11      0.651
   Week 4                       \(16\) 0.38±0.09      \(16\) 0.37±0.10      0.816
   Week 8 dose escalation       \(16\) 0.35±0.12      \(13\) 0.38±0.10      0.507
   Week 12                      \(15\) 0.36±0.13      \(9\) 0.36±0.16       0.591
   Week 16 end of study         \(14\) 0.38±0.12      \(9\) 0.33±0.14       0.403
  Eosinophils (10^9^/L)                                                     
   Screening                    \(16\) 0.19±0.14      \(16\) 0.16±0.12      --
   Baseline                     \(16\) 0.15±0.10      \(16\) 0.15±0.14      0.955
   Week 2                       \(16\) 0.19±0.12      \(16\) 0.16±0.19      0.375
   Week 4                       \(16\) 0.18±0.13      \(16\) 0.16±0.14      0.748
   Week 8 dose escalation       \(16\) 0.17±0.14      \(13\) 0.16±0.12      0.775
   Week 12                      \(15\) 0.22±0.19      \(9\) 0.17±0.19       0.550
   Week 16 end of study         \(14\) 0.17±0.13      \(9\) 0.22±0.17       0.481
  Basophils (10^9^/L)                                                       
   Screening                    \(16\) 0.050±0.028    \(16\) 0.034±0.033    --
   Baseline                     \(16\) 0.041±0.030    \(16\) 0.028±0.038    0.472
   Week 2                       \(16\) 0.049±0.032    \(16\) 0.037±0.035    0.157
   Week 4                       \(16\) 0.035±0.029    \(16\) 0.041±0.036    0.583
   Week 8 dose escalation       \(16\) 0.033±0.031    \(13\) 0.032±0.034    0.890
   Week 12                      \(15\) 0.023±0.026    \(9\) 0.026±0.025     0.897
   Week 16 end of study         \(14\) 0.025±0.032    \(9\) 0.059±0.051     0.090
  Glucose (mmol/L)                                                          
   Screening/baseline           \(16\) 4.83±0.71      \(16\) 4.98±0.53      0.677
  Creatinine (μmol/L)                                                       
   Screening/baseline           \(16\) 66.20±12.20    \(16\) 75.90±15.00    0.054
   Week 16 end of study         \(16\) 65.50±11.90    \(14\) 74.50±13.00    0.058
  eGFR (mL/min/1.73 m^2^)                                                   
   Screening/baseline           \(16\) 84.90±7.20     \(16\) 85.10±6.80     0.787
   Week 16 end of study         \(16\) 85.80±6.90     \(14\) 86.60±6.00     0.588
  AST (U/L)                                                                 
   Screening                    \(16\) 20.50±6.20     \(16\) 24.70±10.80    --
   Baseline                     \(16\) 19.40±3.90     \(16\) 22.90±7.80     0.198
   Week 2                       \(16\) 18.40±4.70     \(16\) 21.80±7.60     0.142
   Week 4                       \(16\) 20.60±7.80     \(16\) 24.40±12.60    0.192
   Week 8 dose escalation       \(16\) 19.20±4.30     \(13\) 23.20±9.80     0.235
   Week 12                      \(15\) 17.80±3.90     \(9\) 22.70±7.70      0.050[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
   Week 16 end of study         \(15\) 18.90±5.60     \(9\) 25.20±8.10      0.034[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
  ALT (U/L)                                                                 
   Screening                    \(16\) 19.50±9.90     \(16\) 33.10±31.90    --
   Baseline                     \(16\) 18.00±7.60     \(16\) 27.30±18.80    0.131
   Week 2                       \(16\) 17.00±6.10     \(16\) 26.10±17.70    0.126
   Week 4                       \(16\) 18.30±13.20    \(16\) 27.10±21.70    0.052
   Week 8 dose escalation       \(16\) 16.50±7.30     \(13\) 28.40±17.90    0.014[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
   Week 12                      \(15\) 16.10±5.80     \(9\) 29.30±17.10     0.017[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
   Week 16 end of study         \(15\) 17.70±11.50    \(9\) 35.30±22.10     0.012[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
  Creatinine kinase (U/L)                                                   
   Baseline                     \(16\) 84.00±43.00    \(16\) 97.00±50.00    0.346
   Week 16 end of study         \(16\) 92.00±45.00    \(14\) 86.00±42.00    0.787
  Homocysteine                                                              
   Baseline                     \(16\) 10.75±2.32     \(16\) 10.31±2.77     0.632
   Week 4                       \(16\) 10.56±2.25     \(16\) 10.75±2.59     0.829
   Week 8 dose escalation       \(16\) 11.25±2.27     \(13\) 9.85±2.30      0.111
   Week 12                      \(15\) 10.67±1.95     \(9\) 8.56±3.81       0.085
   Week 16 end of study         \(15\) 10.20±1.66     \(9\) 9.78±2.05       0.585
  hs-CRP                                                                    
   Baseline                     \(16\) 1.65±1.61      \(16\) 3.51±3.44      0.038[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
   Week 4                       \(16\) 1.69±1.58      \(16\) 3.47±3.33      0.040[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
   Week 8 dose escalation       \(16\) 1.87±1.72      \(13\) 3.42±3.60      0.227
   Week 12                      \(15\) 1.47±1.61      \(9\) 3.24±2.86       0.073
   Week 16 end of study         \(15\) 1.48±1.59      \(9\) 3.27±2.64       0.042[\*](#tfn4-vhrm-10-089){ref-type="table-fn"}
  CoQ10                                                                     
   Baseline                     \(16\) 0.89±0.17      \(16\) 0.93±0.21      0.895
   Week 4                       \(16\) 0.98±0.23      \(16\) 1.03±0.28      0.821
   Week 8 dose escalation       \(16\) 1.08±0.27      \(13\) 1.13±0.37      0.948
   Week 12                      \(15\) 1.11±0.29      \(9\) 1.28±0.45       0.551
   Week 16 end of study         \(15\) 1.15±0.32      \(9\) 1.32±0.45       0.531

**Notes:** Probability values *P*\<0.05 are significant.

*P*-values that were significantly different between groups. The between group statistical significance in red blood cells, MPV and AST values remained within the normal laboratory reference range.

**Abbreviations:** ALT, alanine transaminase; AST, aspartase aminotransferase; CoQ10, Coenzyme Q10; eGFR, estimated glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein; MCH, mean corpuscular hemoglobin; MCV, mean corpuscular volume; MPV, mean platelet volume; RDW, red cell distribution width; SD, standard deviation.
